Combining two types of inhibitors to improve treatment for Acute Myeloid Leukemia
Dual Kinase and LSD1 Inhibition in Acute Myeloid Leukemia
This study is looking at how two types of cancer-fighting drugs can work together to help people with Acute Myeloid Leukemia (AML) by blocking the genes that help cancer cells grow, with the goal of finding better treatments for patients like you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Oregon Health & Science University NIH-funded |
| Lab location | 1 site (Portland, United States) |
| Project ID | NIH-10887555 on NIH RePORTER |
What this research studies
This research investigates the combined effect of kinase inhibitors and LSD1 inhibitors on Acute Myeloid Leukemia (AML). The approach aims to understand how these drugs work together to suppress harmful gene expressions that promote cancer cell growth. By exploring the mechanisms behind this combination therapy, the research seeks to develop more effective treatment options for patients suffering from AML. The study will focus on specific mutations in the cancer cells to tailor the treatment effectively.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with Acute Myeloid Leukemia, particularly those with FLT3 or NRAS mutations.
Not a fit: Patients with other types of leukemia or those who do not have the specific mutations targeted by this research may not benefit.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with Acute Myeloid Leukemia, potentially improving survival rates.
How similar studies have performed: While kinase inhibitors have been used in AML treatment, the combination with LSD1 inhibition is a novel approach that has not been extensively tested in clinical settings.
Where this research is happening
Portland, United States
- Oregon Health & Science University — Portland, United States (Active)
Researchers
- Principal investigator: Braun, Theodore Paul — Oregon Health & Science University
- Study coordinator: Braun, Theodore Paul
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.